cagrilintide novo Nordisk presents new Phase III data for next-gen amylin Another obesity contender just raised

Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control Weight loss: New drug CagriSema leads to 14% weight loss in trial Novo Nordisk A S: CagriSema demonstrated 23% weight loss in an open label head to head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or

SKU: 44640831441 · From iglepidom.org